Analyst Ratings for Cara Therapeutics (CARA)
CARA Rating Summary
CARA Price Target Summary
- Highest: $25.00 (Stifel)
- Lowest: $1.00 (Piper Sandler)
- Average: $12.17
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$12.17 (+1638.1%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 86%
Avg. $ Target:
$12.17 (+1638.1%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 86%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/14/2023 | Piper Sandler | David Amsellem | Downgrade | Neutral (Overweight) |
1.00 (12.00) |
1.05 (0.70) |
-33.33% | Details |
| 5/30/2023 | Jefferies » Updated 6/27/2023 |
Dennis Ding | New Coverage | Buy (N/A) |
18.00 (N/A) |
3.28 (0.70) |
-78.66% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
